-
Je něco špatně v tomto záznamu ?
Current understanding on TREM-2 molecular biology and physiopathological functions
S. Bharadwaj, Y. Groza, JM. Mierzwicka, P. Malý
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, přehledy
- MeSH
- buňky NK imunologie MeSH
- fagocytóza MeSH
- lidé MeSH
- membránové glykoproteiny * metabolismus genetika MeSH
- nádory imunologie metabolismus genetika MeSH
- přirozená imunita MeSH
- receptory imunologické * metabolismus genetika MeSH
- signální transdukce MeSH
- T-lymfocyty imunologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Triggering receptor expressed on myeloid cells 2 (TREM-2), a glycosylated receptor belonging to the immunoglobin superfamily and especially expressed in the myeloid cell lineage, is frequently explained as a reminiscent receptor for both adaptive and innate immunity regulation. TREM-2 is also acknowledged to influence NK cell differentiation via the PI3K and PLCγ signaling pathways, as well as the partial activation or direct inhibition of T cells. Additionally, TREM-2 overexpression is substantially linked to cell-specific functions, such as enhanced phagocytosis, reduced toll-like receptor (TLR)-mediated inflammatory cytokine production, increased transcription of anti-inflammatory cytokines, and reshaped T cell function. Whereas TREM-2-deficient cells exhibit diminished phagocytic function and enhanced proinflammatory cytokines production, proceeding to inflammatory injuries and an immunosuppressive environment for disease progression. Despite the growing literature supporting TREM-2+ cells in various diseases, such as neurodegenerative disorders and cancer, substantial facets of TREM-2-mediated signaling remain inadequately understood relevant to pathophysiology conditions. In this direction, herein, we have summarized the current knowledge on TREM-2 biology and cell-specific TREM-2 expression, particularly in the modulation of pivotal TREM-2-dependent functions under physiopathological conditions. Furthermore, molecular regulation and generic biological relevance of TREM-2 are also discussed, which might provide an alternative approach for preventing or reducing TREM-2-associated deformities. At last, we discussed the TREM-2 function in supporting an immunosuppressive cancer environment and as a potential drug target for cancer immunotherapy. Hence, summarized knowledge of TREM-2 might provide a window to overcome challenges in clinically effective therapies for TREM-2-induced diseases in humans.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013501
- 003
- CZ-PrNML
- 005
- 20240905133828.0
- 007
- ta
- 008
- 240725e20240503ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.intimp.2024.112042 $2 doi
- 035 __
- $a (PubMed)38703564
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Bharadwaj, Shiv $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic. Electronic address: shiv.bharadwaj@ibt.cas.cz
- 245 10
- $a Current understanding on TREM-2 molecular biology and physiopathological functions / $c S. Bharadwaj, Y. Groza, JM. Mierzwicka, P. Malý
- 520 9_
- $a Triggering receptor expressed on myeloid cells 2 (TREM-2), a glycosylated receptor belonging to the immunoglobin superfamily and especially expressed in the myeloid cell lineage, is frequently explained as a reminiscent receptor for both adaptive and innate immunity regulation. TREM-2 is also acknowledged to influence NK cell differentiation via the PI3K and PLCγ signaling pathways, as well as the partial activation or direct inhibition of T cells. Additionally, TREM-2 overexpression is substantially linked to cell-specific functions, such as enhanced phagocytosis, reduced toll-like receptor (TLR)-mediated inflammatory cytokine production, increased transcription of anti-inflammatory cytokines, and reshaped T cell function. Whereas TREM-2-deficient cells exhibit diminished phagocytic function and enhanced proinflammatory cytokines production, proceeding to inflammatory injuries and an immunosuppressive environment for disease progression. Despite the growing literature supporting TREM-2+ cells in various diseases, such as neurodegenerative disorders and cancer, substantial facets of TREM-2-mediated signaling remain inadequately understood relevant to pathophysiology conditions. In this direction, herein, we have summarized the current knowledge on TREM-2 biology and cell-specific TREM-2 expression, particularly in the modulation of pivotal TREM-2-dependent functions under physiopathological conditions. Furthermore, molecular regulation and generic biological relevance of TREM-2 are also discussed, which might provide an alternative approach for preventing or reducing TREM-2-associated deformities. At last, we discussed the TREM-2 function in supporting an immunosuppressive cancer environment and as a potential drug target for cancer immunotherapy. Hence, summarized knowledge of TREM-2 might provide a window to overcome challenges in clinically effective therapies for TREM-2-induced diseases in humans.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a receptory imunologické $x metabolismus $x genetika $7 D011971
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a membránové glykoproteiny $x metabolismus $x genetika $7 D008562
- 650 _2
- $a signální transdukce $7 D015398
- 650 _2
- $a buňky NK $x imunologie $7 D007694
- 650 _2
- $a přirozená imunita $7 D007113
- 650 _2
- $a T-lymfocyty $x imunologie $7 D013601
- 650 _2
- $a nádory $x imunologie $x metabolismus $x genetika $7 D009369
- 650 _2
- $a fagocytóza $7 D010587
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Groza, Yaroslava $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic
- 700 1_
- $a Mierzwicka, Joanna M $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic
- 700 1_
- $a Malý, Petr $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic. Electronic address: petr.maly@ibt.cas.cz
- 773 0_
- $w MED00006034 $t International immunopharmacology $x 1878-1705 $g Roč. 134 (20240503), s. 112042
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38703564 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133822 $b ABA008
- 999 __
- $a ok $b bmc $g 2143364 $s 1225367
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 134 $c - $d 112042 $e 20240503 $i 1878-1705 $m International immunopharmacology $n Int Immunopharmacol $x MED00006034
- LZP __
- $a Pubmed-20240725